Manchester Capital Management LLC Boosts Stock Position in Humana Inc. (NYSE:HUM)

Manchester Capital Management LLC boosted its holdings in Humana Inc. (NYSE:HUM) by 6.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 830 shares of the insurance provider’s stock after purchasing an additional 47 shares during the period. Manchester Capital Management LLC’s holdings in Humana were worth $211,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Creative Financial Designs Inc. ADV raised its stake in shares of Humana by 244.0% in the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after buying an additional 61 shares during the period. Ashton Thomas Securities LLC bought a new stake in shares of Humana in the third quarter valued at $31,000. Your Advocates Ltd. LLP raised its stake in shares of Humana by 81.8% in the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after buying an additional 45 shares during the period. Atwood & Palmer Inc. raised its stake in shares of Humana by 64.5% in the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock valued at $39,000 after buying an additional 60 shares during the period. Finally, LRI Investments LLC raised its stake in shares of Humana by 1,021.4% in the third quarter. LRI Investments LLC now owns 157 shares of the insurance provider’s stock valued at $50,000 after buying an additional 143 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on HUM shares. Cantor Fitzgerald reiterated a “neutral” rating and set a $290.00 price objective on shares of Humana in a research note on Wednesday. Piper Sandler boosted their price objective on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Truist Financial boosted their price objective on Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research note on Monday, January 6th. Royal Bank of Canada reiterated an “outperform” rating and set a $283.00 price objective on shares of Humana in a research note on Wednesday. Finally, Wells Fargo & Company decreased their price objective on Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Nineteen analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $293.05.

Insider Buying and Selling

In related news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.32% of the stock is owned by corporate insiders.

Humana Price Performance

HUM opened at $253.61 on Friday. The stock’s 50 day simple moving average is $271.27 and its 200 day simple moving average is $294.21. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $406.46. The firm has a market cap of $30.54 billion, a price-to-earnings ratio of 22.46, a PEG ratio of 2.11 and a beta of 0.56.

Humana (NYSE:HUM) last posted its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 13.20% and a net margin of 1.18%. As a group, analysts predict that Humana Inc. will post 16.11 earnings per share for the current year.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.